|Click to Enlarge|
- no NGS testing (neither NCD nor LCD) or
- alternatively can get testing for non-targeted-therapy tests (e.g. minimal residual disease tests),
- depending on a sentence on page 4 about the scope of the NCD.
In this sentence, CMS writes that the NCD applies only to NGS tests to choose targeted therapies or assign patients to targeted therapy trials.
The LCD pathway is not specific for indication, though it is specific for advanced cancer and 1 use of a test.
The green boxes show the route to guaranteed NCD coverage: NGS technology & patient has advanced cancer & test is FDA companion diagnostic & patient's cancer is on-label for test & patient has not had this test for this cancer before.
For my long article on implications of the NCD, see here.